What is the appropriate initial workup for suspected dermatomyositis?

Dermatomyositis Workup

The initial workup for suspected dermatomyositis requires a comprehensive laboratory panel including muscle enzymes (CPK, LDH, AST, ALT, aldolase), myositis-specific antibodies, complete blood count, inflammatory markers, and systematic organ screening with ECG, echocardiogram, pulmonary function tests, and MRI of muscles, with muscle biopsy reserved for atypical presentations lacking characteristic rash. 1

Essential Laboratory Investigations

Core Muscle and Inflammatory Markers

• Muscle enzymes: CPK, LDH, AST (SGOT), ALT (SGPT), and aldolase if available 1
• Complete blood count and blood film 1
• ESR (or plasma viscosity) and CRP 1
• Troponin to evaluate myocardial involvement 2, 3, 4

Autoantibody Testing

• Myositis-specific and myositis-associated antibodies are critical for diagnosis, phenotype identification, and predicting extramuscular organ involvement 1, 2
• These antibodies help define clinical subgroups and guide workup for specific complications like interstitial lung disease 2

Exclusion of Alternative Diagnoses

• Renal and liver function tests 1
• Infection screen for differential diagnosis 1
• Thyroid function, electrolyte panel, vitamin D levels to exclude endocrine and metabolic causes 1
• Tests for metabolic/mitochondrial myopathies, especially when rash is absent or presentation is atypical 1
• Urine dipstick with further evaluation if protein is present 1

Organ-Specific Assessments

Cardiac Evaluation

• ECG and echocardiogram at diagnosis in all patients 1
• Cardiac involvement can significantly impact morbidity and mortality 2

Pulmonary Assessment

• Pulmonary function tests including CO diffusion at diagnosis 1
• Chest X-ray and HRCT if pulmonary function tests suggest interstitial lung disease or if clinical concern exists 1
• Interstitial lung disease occurs commonly and requires early detection 2

Muscle Assessment

• Formal muscle strength testing using validated measures such as MMT8 (Manual Muscle Test) and CMAS (Childhood Myositis Assessment Scale) 1
• MRI of muscles using T2-weighted/STIR sequences to detect inflammation, aid diagnosis, and monitor disease activity 1, 2, 1, 2
• MRI should be interpreted by an expert radiologist and can guide biopsy site selection 1

Skin Assessment

• Nailfold capillaroscopy at diagnosis and during follow-up to assess microvascular changes 1
• Formal Cutaneous Assessment Tool (CAT) to document and monitor skin disease activity 1
• Look for pathognomonic features: Gottron's papules, heliotrope rash, periungual telangiectasias 2

Swallowing Function

• Formal swallow assessment in every patient, potentially including speech and language therapy evaluation or video fluoroscopy/barium studies 1
• Pharyngeal muscle involvement can lead to aspiration risk 2

Additional Diagnostic Studies

Muscle Biopsy

• Indicated when presentation is atypical, particularly in the absence of rash or skin signs 1
• Use standardized JDM biopsy score tool to quantify histological abnormalities 1
• Requires expert histopathological interpretation 1
• Insufficient evidence to recommend needle versus open biopsy in children 1

Electromyography (EMG)

• Consider when diagnosis is uncertain to differentiate myopathy from neuropathy or neuromuscular junction disorders 1
• EMG shows polyphasic motor unit action potentials of short duration and low amplitude with increased insertional activity 2
• Important caveat: EMG does not reliably detect metabolic myopathies; further workup required if suspected 1

Alternative Imaging

• Muscle ultrasound (when performed by experienced sonographer) may show increased echo intensity indicative of myositis when MRI or biopsy unavailable 1
• MRI brain if neurological involvement suspected 1
• Abdominal ultrasound 1

Critical Clinical Considerations

Malignancy Screening

Approximately 20-30% of adult dermatomyositis cases are associated with malignancy, with higher occurrence in men and elderly patients 2, 5, 6. While extensive screening recommendations vary, age-appropriate cancer screening should be performed, particularly in adults over 40 years 2, 7.

Alternative Diagnoses to Exclude

When cutaneous signs are absent or response to therapy is inadequate, strongly consider metabolic myopathies, mitochondrial disorders, and muscular dystrophies 1. This is critical to avoid misdiagnosis and inappropriate treatment.

Timing and Prioritization

The 2017 Annals of the Rheumatic Diseases consensus guidelines represent the most comprehensive and recent framework, achieving 94-100% expert agreement on diagnostic recommendations 1. These should guide the systematic approach to workup, with MRI and autoantibody testing providing crucial diagnostic and prognostic information 2.